Skip to content
Open access

Molecular mechanism of KRAS binding to BRAF and its regulation by the BRAF-specific region

Oct 2026 · Structure · 0 citations · 54 references
Medicine

TL;DR

Although the RBD engages KRAS through a conserved mechanism, the BRAF(CRD) adopts a hinge-like displacement away from KRAS, forming fewer contacts and contributing less to binding than CRAF(CRD).

Abstract

SUMMARY MAPK pathway activation requires recruitment of RAF kinases by GTP-bound RAS through the RAS-binding domain (RBD) and cysteine-rich domain (CRD). BRAF uniquely contains an N-terminal BRAF-specific region (BSR), but the structural basis of KRAS engagement and BSR function remain unclear. Here, we report the structure of KRAS bound to BRAF(RBD-CRD) and compare it with KRAS-CRAF(RBD-CRD). Although the RBD engages KRAS through a conserved mechanism, the BRAF(CRD) adopts a hinge-like displacement away from KRAS, forming fewer contacts and contributing less to binding than CRAF(CRD). Structural analysis, biophysical measurements, and AlphaFold3 modeling show that the BSR does not directly contact KRAS but instead regulates RBD accessibility through a cis-acting mechanism that requires linkage to the RBD. Without the CRD, the BSR-RBD linker restricts KRAS binding, whereas CRD inclusion stabilizes BSR positioning and partially relieves inhibition. Disease-associated mutations further support a regulatory role for BRAF(CRD), defining an isoform-specific mechanism regulating RAF activation.

Read PDF

Similar papers

Open access Oct 2026

Kinetic signatures of RAS-BRAF engagement reveal isoform selectivity, oncogenic amplification, and mutation-dependent inhibitor resistance.

The RAS-RAF-MEK-ERK (MAPK) signaling cascade is a central regulator of cellular proliferation and differentiation, and its dysregulation is a frequent driver of oncogenesis. RAF activation requires recruitment by GTP-bound RAS at the plasma membrane; however, the precise molecular determinants governing RAS-RAF engagem...

Sravani Malasani, Zhi-Hong Wang · 0 citations
Review Open access Oct 2026

Blockade of mutant RAS oncogenic signaling: a 2026 update.

Daraxonrasib, which is an indirect inhibitor of wildtype and mutant H/K/NRAS isoforms, is FDA approved for the second-line treatment of all RAS-mutant pancreatic cancers.

R. Roskoski · 0 citations
Open access Oct 2026

Cryo-EM and biochemical characterization of a BRAF/CRAF heterodimer shows that the NtA motif negative charge is dispensable for RAF activation.

Upon RAS-driven membrane recruitment, RAF kinases ARAF, BRAF, and CRAF are activated through homo- or heterodimerization to initiate MAP kinase signaling. Although RAF heterodimers drive physiologic and oncogenic signaling, they remain little studied structurally and biochemically. Here, we report the preparation, bioc...

Byung Hak Ha, Emre Tkacik, D. Gazgalis et al. · 1 citation
Open access Sep 2026

Structural mechanisms underlying resistance to Switch-II pocket inhibitors in KRAS

Direct targeting of KRAS through the Switch-II pocket is an effective therapeutic strategy, but acquired resistance limits clinical benefit. We examine clinically observed resistance mutations (R68S, H95Q, Y96C, Y96D and Q99L) arising during KRAS G12C inhibitor therapy using biochemical, structural, computational and c...

M. J. Whitley, M. Dyba, Mayukh Chakrabarti et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.